Postoperative Opioid Prescribing After Female Pelvic Medicine and Reconstructive Surgery.

IF 1.4 4区 医学 Q3 OBSTETRICS & GYNECOLOGY Female Pelvic Medicine and Reconstructive Surgery Pub Date : 2021-11-01 DOI:10.1097/SPV.0000000000001113
Krista M L Reagan, Sarah H Boyles, Taylor J Brueseke, Brian J Linder, Marcella G Willis-Gray, Sara B Cichowski, Jaime B Long
{"title":"Postoperative Opioid Prescribing After Female Pelvic Medicine and Reconstructive Surgery.","authors":"Krista M L Reagan,&nbsp;Sarah H Boyles,&nbsp;Taylor J Brueseke,&nbsp;Brian J Linder,&nbsp;Marcella G Willis-Gray,&nbsp;Sara B Cichowski,&nbsp;Jaime B Long","doi":"10.1097/SPV.0000000000001113","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to provide female pelvic medicine and reconstructive surgery (FPMRS) providers with evidence-based guidance on opioid prescribing following surgery.</p><p><strong>Methods: </strong>A literature search of English language publications between January 1, 2000, and March 31, 2021, was conducted. Search terms identified reports on opioid prescribing, perioperative opioid use, and postoperative pain after FPMRS procedures. Publications were screened, those meeting inclusion criteria were reviewed, and data were abstracted. Data regarding the primary objective included the oral morphine milligram equivalents of opioid prescribed and used after discharge. Information meeting criteria for the secondary objectives was collected, and qualitative data synthesis was performed to generate evidence-based practice guidelines for prescription of opioids after FPMRS procedures.</p><p><strong>Results: </strong>A total of 6,028 unique abstracts were identified, 452 were screened, and 198 full-text articles were assessed for eligibility. Fifteen articles informed the primary outcome, and 32 informed secondary outcomes.</p><p><strong>Conclusions: </strong>For opioid-naive patients undergoing pelvic reconstructive surgery, we strongly recommend surgeons to provide no more than 15 tablets of opioids (roughly 112.5 morphine milligram equivalents) on hospital discharge. In cases where patients use no or little opioids in the hospital, patients may be safely discharged without postoperative opioids. Second, patient and surgical factors that may have an impact on opioid use should be assessed before surgery. Third, enhanced recovery pathways should be used to improve perioperative care, optimize pain control, and minimize opioid use. Fourth, systemic issues that lead to opioid overprescribing should be addressed. Female pelvic medicine and reconstructive surgery surgeons must aim to balance adequate postoperative pain control with individual and societal risks associated with excess opioid prescribing.</p>","PeriodicalId":48831,"journal":{"name":"Female Pelvic Medicine and Reconstructive Surgery","volume":"27 11","pages":"643-653"},"PeriodicalIF":1.4000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Female Pelvic Medicine and Reconstructive Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SPV.0000000000001113","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 8

Abstract

Objective: This study aimed to provide female pelvic medicine and reconstructive surgery (FPMRS) providers with evidence-based guidance on opioid prescribing following surgery.

Methods: A literature search of English language publications between January 1, 2000, and March 31, 2021, was conducted. Search terms identified reports on opioid prescribing, perioperative opioid use, and postoperative pain after FPMRS procedures. Publications were screened, those meeting inclusion criteria were reviewed, and data were abstracted. Data regarding the primary objective included the oral morphine milligram equivalents of opioid prescribed and used after discharge. Information meeting criteria for the secondary objectives was collected, and qualitative data synthesis was performed to generate evidence-based practice guidelines for prescription of opioids after FPMRS procedures.

Results: A total of 6,028 unique abstracts were identified, 452 were screened, and 198 full-text articles were assessed for eligibility. Fifteen articles informed the primary outcome, and 32 informed secondary outcomes.

Conclusions: For opioid-naive patients undergoing pelvic reconstructive surgery, we strongly recommend surgeons to provide no more than 15 tablets of opioids (roughly 112.5 morphine milligram equivalents) on hospital discharge. In cases where patients use no or little opioids in the hospital, patients may be safely discharged without postoperative opioids. Second, patient and surgical factors that may have an impact on opioid use should be assessed before surgery. Third, enhanced recovery pathways should be used to improve perioperative care, optimize pain control, and minimize opioid use. Fourth, systemic issues that lead to opioid overprescribing should be addressed. Female pelvic medicine and reconstructive surgery surgeons must aim to balance adequate postoperative pain control with individual and societal risks associated with excess opioid prescribing.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
女性盆腔内科及重建手术术后阿片类药物处方。
目的:本研究旨在为女性骨盆医学和重建手术(FPMRS)提供者提供术后阿片类药物处方的循证指导。方法:检索2000年1月1日至2021年3月31日英文出版物的文献。搜索词确定了关于阿片类药物处方、围手术期阿片类药物使用和FPMRS手术后术后疼痛的报告。对出版物进行筛选,对符合纳入标准的出版物进行审查,并对数据进行摘要。关于主要目标的数据包括处方和出院后使用的阿片类药物的口服吗啡毫克当量。收集符合次要目标标准的信息,并进行定性数据合成,以生成FPMRS手术后阿片类药物处方的循证实践指南。结果:共鉴定出6028篇独特摘要,筛选了452篇,评估了198篇全文文章的入选资格。15篇报道了主要结局,32篇报道了次要结局。结论:对于接受骨盆重建手术的阿片类药物新手患者,我们强烈建议外科医生在出院时提供不超过15片阿片类药物(大约112.5吗啡毫克当量)。如果患者在医院不使用或很少使用阿片类药物,患者可以在术后不使用阿片类药物的情况下安全出院。其次,术前应评估可能影响阿片类药物使用的患者和手术因素。第三,加强康复途径应用于改善围手术期护理,优化疼痛控制,并尽量减少阿片类药物的使用。第四,应解决导致阿片类药物过度处方的系统性问题。女性骨盆医学和重建外科医生必须致力于平衡足够的术后疼痛控制与过量阿片类药物处方相关的个人和社会风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.10
自引率
12.50%
发文量
228
期刊介绍: Female Pelvic Medicine & Reconstructive Surgery, official journal of the American Urogynecologic Society, is a peer-reviewed, multidisciplinary journal dedicated to specialists, physicians and allied health professionals concerned with prevention, diagnosis and treatment of female pelvic floor disorders. The journal publishes original clinical research, basic science research, education, scientific advances, case reports, scientific reviews, editorials and letters to the editor.
期刊最新文献
AUGS-PERFORM: A New Patient-Reported Outcome Measure to Assess Quality of Prolapse Care. Factors Associated With a Positive Urine Culture in Women Seeking Urogynecologic Care for Urinary Tract Infection Symptoms. Complications Reported to the Food and Drug Administration: A Cross-sectional Comparison of Urogynecologic Meshes. The Role of Pessaries in the Treatment of Women With Stress Urinary Incontinence: A Systematic Review and Meta-Analysis. The Impact of Methenamine Hippurate Treatment on Urothelial Integrity and Bladder Inflammation in Aged Female Mice and Women With Urinary Tract Infections.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1